| Jay A Mcdonald, MD | |
|
22 N Medical Park Dr, Fishersville, VA 22939-2344 | |
| (540) 932-5373 | |
| (540) 932-5382 |
| Full Name | Jay A Mcdonald |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 22 N Medical Park Dr, Fishersville, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619069127 | NPI | - | NPPES |
| 006700128 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 0101044450 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jay A Mcdonald, MD 500 Ray C Hunt Dr, Charlottesville, VA 22903-2981 Ph: (434) 980-6140 | Jay A Mcdonald, MD 22 N Medical Park Dr, Fishersville, VA 22939-2344 Ph: (540) 932-5373 |
News Archive
The Sixty-ninth World Health Assembly closed today after approving new resolutions on WHO's Framework for Engagement with Non-State Actors; the Sustainable Development Goals; the International Health Regulations; tobacco control; road traffic deaths and injuries; nutrition; HIV, hepatitis and STIs; mycetoma; research and development; access to medicines and integrated health services.
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.
Professor Füsgen presented his findings at the European Geriatrics Congress in Vienna, which ended yesterday (September 19). They show that the symptoms of hyponatraemia (low sodium level in the blood), which are tiredness, difficulty in concentrating and loss of balance, can develop into confusion and even coma if left untreated.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 4 days ago
Michelle A. Brooks, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 57 Beam Ln Ste 202, Fishersville, VA 22939 Phone: 540-932-0980 Fax: 434-932-0979 | |
Rebecca L Isbell, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 22 N Medical Park Dr, Fishersville, VA 22939 Phone: 540-932-5373 Fax: 540-932-5382 | |
John Stephen Campbell, M.D Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 184 Hickory Hill Rd, Fishersville, VA 22939 Phone: 540-932-2222 Fax: 540-886-7364 | |
Michael L Gwaltney, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 78 Medical Center Dr, Fishersville, VA 22939 Phone: 540-932-4075 Fax: 540-932-5199 | |
Samuel Cross, Pediatrics Medicare: Medicare Enrolled Practice Location: 57 Beam Ln Ste 202, Fishersville, VA 22939 Phone: 540-932-0980 Fax: 540-932-0979 | |
Mr. Evan B Karp, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 57 Beam Ln Ste 202, Fishersville, VA 22939 Phone: 540-932-0980 Fax: 540-932-0979 | |
Connie S. Jones, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 78 Medical Center Dr, Fishersville, VA 22939 Phone: 800-249-5835 |